Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

177Lu-TLX591

Radiopharmaceutical · developed by Telix Pharmaceuticals Pty

Phase 3 Most advanced trial

TLX Developer

1 Registered trials

What is 177Lu-TLX591?

177Lu-TLX591 is a lutetium-177 radiopharmaceutical being studied in metastatic castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Lutetium (177Lu) rosopatamab tetraxetan
Drug type: Radiopharmaceutical
Therapy area: Oncology
Developer: Telix Pharmaceuticals Pty Limited (TLX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06520345	Phase 3	Metastatic Castration-resistant Prostate Cancer	Recruiting	TLX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Castration-resistant Prostate Cancer

More from Telix Pharmaceuticals Pty

177Lu girentuximab Phase 1/2 89Zr-DFOsq-olaratumab Phase 1 Copper Cu 64-DOTA-TLX592 Early Phase 1 Iodine I 131 IPA Phase 1 Lutetium Lu 177 Rosopatamab Tetraxetan Phase 2 Samarium Sm 153-DOTMP Phase 1 Zirconium Zr 89 Girentuximab Phase 3

Sources

ClinicalTrials.gov NCT06520345

Updated Oct 3, 2026. Something wrong or missing? Report it on the TLX page.

Follow TLX, the company behind 177Lu-TLX591

See TLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TLX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z